Pharming Group (NASDAQ:PHAR) Shares Gap Up – Here’s What Happened

Pharming Group (NASDAQ:PHAR)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $7.35, but opened at $7.62. Pharming Group shares last traded at $7.63, with a volume of 8,676 shares changing hands.

Analyst Ratings Changes

PHAR has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research report on Thursday, October 24th. Oppenheimer cut their target price on Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, October 28th.

Pharming Group Stock Performance

The stock has a market capitalization of $529.11 million, a PE ratio of -29.35 and a beta of 0.13. The business’s fifty day moving average is $8.24 and its two-hundred day moving average is $8.20. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of Pharming Group (NASDAQ:PHAR) by 32.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,435 shares of the company’s stock after acquiring an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.